

## IN THE CLAIMS:

Please amend the claims as follows:

CB SUB D2  
Claim 1 (amended). A topically-applicable photodynamic medicament, the medicament comprising at least one halogenated xanthene as a photoactive component, wherein said medicament is useful for treatment of diseases of human and animal tissue.

Claim 4 (amended). The medicament of Claim 1 wherein said halogenated xanthene includes at least one compound selected from the group consisting of 4',5'-Dichlorofluorescein; 2',7'-Dichlorofluorescein; 4,5,6,7-Tetrachlorofluorescein; 2',4',5',7'-Tetrachlorofluorescein; Dibromofluorescein; Solvent Red 72; Diiodofluorescein; Eosin B; Eosin Y; Ethyl Eosin; Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein.

Claim 6 (amended). The medicament of Claim 5 wherein said targeting moiety is selected from the group consisting of deoxyribonucleic acids (DNA), ribonucleic acids (RNA), amino acids, proteins, antibodies, ligands, haptens, carbohydrate receptors, carbohydrate complexing agents, lipid receptors, lipid complexing agents, protein receptors, protein complexing agents, chelators, encapsulating vehicles, short-chain aliphatic hydrocarbons, long-chain aliphatic hydrocarbons, aromatic hydrocarbons, aldehydes, ketones, alcohols, esters, amides, amines, nitriles, azides, hydrophilic moieties and hydrophobic moieties.

Claim 7 (amended). The medicament of Claim 1 wherein said medicament is formulated in a delivery vehicle selected from the group consisting of a liquid, a semisolid, a solid and an aerosol

Claim 8 (twice amended). The medicament of Claim 7 wherein said vehicle is selected from the group consisting of an aqueous suspension, a non-aqueous suspension, a nanoparticulate suspension, a solution, a cream, an ointment, a gel, a syrup, a suppository and a micro-droplet spray.

C<sup>5</sup>  
Claim 9 (amended). The medicament of Claim 1 wherein said halogenated xanthene is in a delivery vehicle that includes at least one selected from the group consisting of a builder, a stabilizer, an emulsifier, a dispersant, a preservative, a buffer, an electrolyte, a tissue penetrating agent and a tissue softening agent.

Claim 10 (amended). The medicament of Claim 1 wherein said medicament is useful for the treatment of indications selected from the group consisting of diseases of the skin and related organs, diseases of the mouth and digestive tract and related organs, diseases of the urinary and reproductive tracts and related organs, diseases of the respiratory tracts and related organs, diseases of other internal and external tissue surfaces, tissue surfaces exposed during surgery, and microbial or parasitic infection.

---

Cancel Claim 11.

Claim 12 (amended). The method of Claim 1 wherein said medicament is activated using light having a wavelength of between approximately 500 nm and 600 nm.

Claim 13 (amended). Use of a halogenated xanthene as a photoactive component in the preparation of a topical medicament for treatment of human and animal tissue using photodynamic therapy by adding said halogenated xanthene to a delivery vehicle.

Claim 14 (amended). The use of Claim 13 for preparation of a medicament for the treatment of indications selected from the group consisting of diseases of the skin and related organs, diseases of the mouth and digestive tract and related organs, diseases of the urinary and reproductive tracts and related organs, diseases of the respiratory tracts and related organs, diseases of other internal and external tissue surfaces, tissue surfaces exposed during surgery, and microbial or parasitic infection.

Claim 16 (amended). The use of Claim 13 wherein said medicament is for photodynamic therapy with activating light having a wavelength of between approximately 500 nm and 600 nm.

Claim 19 (amended). The use of Claim 17 wherein said halogenated xanthene is photoactivated with light having a wavelength of between approximately 500 nm and 600 nm.

Cancel Claim 20.

Claim 24 (amended). The pharmaceutical composition of Claim 21 wherein said halogenated xanthene includes at least one compound selected from the group consisting of 4',5'-Dichlorofluorescein; 2',7'-Dichlorofluorescein; 4,5,6,7-Tetrachlorofluorescein; 2',4',5',7'-Tetrachlorofluorescein; Dibromofluorescein; Solvent Red 72; Diiodofluorescein; Eosin B; Eosin Y; Ethyl Eosin; Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein.

Claim 26 (amended). The pharmaceutical composition of Claim 25 wherein said targeting moiety is selected from the group consisting of deoxyribonucleic acids (DNA), ribonucleic acids (RNA), amino acids, proteins, antibodies, ligands, haptens, carbohydrate receptors, carbohydrate complexing agents, lipid receptors, lipid complexing agents, protein receptors, protein complexing agents, chelators, encapsulating vehicles, short-chain aliphatic hydrocarbons, long-chain aliphatic, aromatic hydrocarbons, aldehydes, ketones, alcohols, esters, amides, amines, nitriles, azides, hydrophilic moieties and hydrophobic moieties.

Claim 27 (amended). The pharmaceutical composition of Claim 21 wherein said pharmaceutical composition is formulated in a delivery vehicle selected from the group consisting of a liquid, a semisolid, a solid and an aerosol.

Claim 28 (amended). The pharmaceutical composition of Claim 27 wherein said vehicle is selected from the group consisting of an aqueous suspension, a non-aqueous suspension, a nanoparticulate suspension, a solution, a cream, an ointment, a gel, a syrup, a suppository and a micro-droplet spray.

C<sup>10</sup>  
Claim 29 (amended). The pharmaceutical composition of Claim 21 wherein said halogenated xanthene is in a delivery vehicle that includes at least one selected from the group consisting of a builder, a stabilizer, an emulsifier, a dispersant, a preservative, a buffer, an electrolyte, a tissue penetrating agent and a tissue softening agent.

Claim 30 (amended). The pharmaceutical composition of Claim 21 wherein said photodynamic therapy uses activating light having a wavelength of between approximately 500 nm and 600 nm.

Cancel Claim 31.

Claim 32 (amended). A method of treating diseased tissue comprising:  
topically applying a medicament including at least one halogenated xanthene to or proximate to diseased human or animal tissue; and  
illuminating said human or animal tissue with light to photoactivate said halogenated xanthene present within or proximate to said tissue.

211  
SUB  
181

C<sup>11</sup>  
Claim 33 (amended). The method of Claim 32 wherein said diseased human or animal tissue comprises the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tracts and related organs, other internal and external tissue surfaces, tissue surfaces exposed during surgery, and tissue with microbial or parasitic infection.

Claim 34 (amended). The method of Claim 32 wherein said step of illuminating uses light having a wavelength of between approximately 500 nm and 600 nm.

Cancel Claim 35.

Claim 36 (amended). A topically-applicable medicament comprising at least one halogenated xanthene as a photoactive component, wherein such medicament is useful for photodynamic treatment of human and animal tissue.

*Amended*  
*Sub a*  
*D*  
Claim 37 (amended). A topically-applicable medicament comprising at least one halogenated xanthene as a primary active component, wherein such medicament is useful for photodynamic treatment of indications selected from the group consisting of diseases of the skin and related organs, diseases of the mouth and digestive tract and related organs, diseases of the urinary and reproductive tracts and related organs, diseases of the respiratory tracts and related organs, diseases of other internal and external tissue surfaces, tissue surfaces exposed during surgery, and microbial or parasitic infection.